Seattle Genetics Leads Roche in Race to Develop Cancer Combo

Seattle Genetics Inc. and Takeda Pharmaceutical Co. may beat Roche Holding AG in developing a new type of combination cancer therapy that’s less toxic than standard treatments.
Bloomberg